Phase II/III (Integrated)

392 trials 186 recruiting

Filter these 392 trials by condition, country, sponsor and more.

Open in Search →

Open-label Study of ELA026 in Participants with sHLH (short title) Recruiting

2025-520624-25-00 Secondary Hemophagocytic Lymphohistiocytosis (sHLH) 2025-09-19
Impact of dapagliflozin for the regulation of immunological activity in Membranous Nephropathy Recruiting

2023-507658-34-00 Membranous Nephropathy 2025-09-19
Melatonin versus quetiapine in adolescents (MEL-QUE-A) Recruiting

2024-519597-39-00 Psychiatric disorder (ICD-10 F20-F69, F84, F90-F95) and 2025-08-18
Restarting Early versus Later Anticoagulation for Chronic Subdural Hematoma with Atrial Fibrillation (RELACS) Recruiting

2025-521179-29-00 Chronic subdural hematoma 2025-07-06
A phase 2/3, multi-center, study of L-Annamycin in combination with cytarabine vs. placebo in combination with cytarabine as second line the… Recruiting

2024-518359-47-00 Acute Myeloid Leukemia 2025-06-17
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10… Recruiting

2024-512659-19-00 Advanced Melanoma 2025-03-31
Clinical trial to study the effect of an already authorized drug on other pathologies by administering it to people with a recent diagnosis … Recruiting

2024-519778-38-00 squizophrenia 2024-12-02
A phase 3 multi-center trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids in children (ag… Recruiting

2023-503630-44-00 Treatment of moderate-to-severe Atopic dermatitis 2024-11-20
Randomized phase II study comparing 5FU/LV+Nal-IRI, gemcitabine+Nab-paclitaxel or a sequential regimen of 2 months 5FU/LV+Nal-IRI followed b… Recruiting

2024-518143-38-00 Metastatic pancreatic cancer 2024-10-25
An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib Study Recruiting

2024-512217-40-00 Malignant Solid Tumors 2024-10-11
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents with Fabry Disease Recruiting

2022-503128-29-00 Fabry's disease 2024-10-08
Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting

2023-504231-41-01 Locally advanced or metastatic urothelial cancer 2024-10-02
A Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE® and Narrow-Band Ultraviolet B (NB-UVB) Light versu… Recruiting

2023-507470-40-00 Vitiligo 2024-08-27
A Study of Zanubrutinib Versus Tacrolimus in Participants With Primary Membranous Nephropathy (ALMOND) Recruiting

2022-501147-32-00 Primary Membranous Nephropathy 2024-07-11
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial Recruiting

2022-501551-90-00 Prostate cancer 2023-12-13
Safety and efficacy of anakinra treatment for patients with persistent respiratory symptoms post acute covid and immune system activation: t… Recruiting

2023-508123-12-00 Post-Acute COVID Syndrome (PACS) 2023-11-03
Open-label, long-term safety, efficacy, and pharmacokinetics study of vibegron in pediatric subjects 2 years to < 18 years of age with NDO a… Recruiting

2024-513995-16-00 Neurogenic Detrusor Overactivity (NDO) 2023-07-28
Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting

2022-500273-14-00 Atherosclerotic cardiovascular disease in patients with 2023-07-17
A Phase 2/3 Safety, Pharmacokinetics, and Efficacy Study ofNirmatrelvir/Ritonavir in Pediatric, Nonhospitalized Symptomatic Participants Wit… Recruiting

2023-509773-23-00 SARS-CoV-2 Infection 2023-07-13
OLE study in participants with pulmonary arterial hypertension Recruiting

2023-505539-11-00 Pulmonary Arterial Hypertension 2023-04-06
A Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus BSC versus Placebo plus BSC in Participants with IPS… Recruiting

2022-500479-29-00 International Prognostic Scoring System-Revised (IPSS-R 2023-03-28
Satisfaction study of split doses botulinum toxin with double frequency Recruiting

2025-520915-14-00 Wrinkles, fine lines 2023-01-12
Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting

2023-506548-18-00 Dermatitis atopic 2022-11-10
An extension phase 2/3 study to test the safety of long term administration of oral PHA-022121 for acute treatment of angioedema attacks in … Recruiting

2023-505766-28-00 Hereditary angioedema 2022-10-10